About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Braf
Braf transforming gene
MGI:88190
52 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Braftm1.1Brd/Braf+
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Tg(Vil1-cre)997Gum/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL 		increased carcinoma incidence J:199307
increased intestinal adenoma incidence J:199307
Braftm1.1Brd/Braf+
Tg(Vil1-cre)997Gum/0
Trp53tm2Tyj/Trp53tm2Tyj
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * SJL 		abnormal tumor pathology J:199307
increased metastatic potential J:199307
Braftm1Cpri/Braf+
Grprtm1Jfb/?
Scn10atm2(cre)Jwo/Scn10a+
involves: 129 * 129P2/OlaHsd * 129X1/SvJ 		normal behavior/neurological phenotype J:205122
Braftm1Cpri/Braf+
Grptm1Jfb/Grptm1Jfb
Scn10atm2(cre)Jwo/Scn10a+
involves: 129 * 129P2/OlaHsd * 129X1/SvJ * C57BL/6J 		normal behavior/neurological phenotype J:205122
Braftm1Cpri/Braftm1Cpri
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-cre/ERT2)1Lru/0
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL 		increased incidence of tumors by chemical induction J:147434
increased melanoma incidence J:147434
increased skin tumor incidence J:147434
Braftm1Cpri/Braftm1Cpri
Gnastm3Lsw/Gnastm3Lsw
Tg(TPO-cre)1Shk/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * FVB/NCr 		increased thyroid tumor incidence J:168249
Braftm1Cpri/Braftm1Cpri
Tshrtm1Rmar/Tshrtm1Rmar
Tg(TPO-cre)1Shk/0
involves: 129P2/OlaHsd * 129S1/Sv * FVB/NCr 		abnormal thyroid follicle morphology J:168249
increased thyroid tumor incidence J:168249
small thyroid gland J:168249
Braftm1Mmcm/Braf+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd 		abnormal lung morphology J:121715
increased lung adenocarcinoma incidence J:121715
increased lung tumor incidence J:121715
Braftm1Mmcm/Braf+
Trp53tm1Brn/Trp53tm3.1Tyj
Tg(TPO-cre/ERT2)1139Tyj/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac 		increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Ptentm1Mro/Ptentm1Mro
Tg(Tyr-cre/ERT2)1Lru/0
B6.Cg-Braftm1Mmcm Tg(Tyr-cre/ERT2)1Lru Ptentm1Mro 		decreased tumor-free survival time J:188523
increased cutaneous melanoma incidence J:188523
premature death J:188523
spontaneous skin ulceration J:188523
Braftm1Mmcm/Braf+
Ptentm2.1Ppp/Pten+
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S1/Sv * FVB 		abnormal melanocyte morphology J:151023
increased cutaneous melanoma incidence J:151023
Braftm1Mmcm/Braf+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S1/Sv * FVB 		increased cutaneous melanoma incidence J:151023
increased metastatic potential J:151023
Braftm1Mmcm/Braf+
Cdkn2atm4Rdp/Cdkn2atm4Rdp
involves: 129P2/OlaHsd 		increased lung tumor incidence J:121715
Braftm1Mmcm/Braf+
Trp53tm3.1Tyj/Trp53+
Tg(TPO-cre/ERT2)1139Tyj/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac 		increased thyroid carcinoma incidence J:208854
premature death J:208854
Braftm1Mmcm/Braf+
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Tg(Mitf-cre)7114Gsb/0
STOCK Braftm1Mmcm Gt(ROSA)26Sortm14(CAG-tdTomato)Hze Tg(Mitf-cre)7114Gsb/Cvrk 		abnormal cell physiology J:312561
increased tail pigmentation J:312561
Braftm1Mmcm/Braf+
Ptentm1Rdp/Ptentm1Rdp
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N 		increased cutaneous melanoma incidence J:151023
increased metastatic potential J:151023
Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac 		decreased tumor-free survival time J:208854
increased metastatic potential J:208854
increased thyroid carcinoma incidence J:208854
increased thyroid-stimulating hormone level J:208854
respiratory failure J:208854
Braftm1Mmcm/Braf+
Ezh2tm1.1Nesh/Ezh2+
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB 		increased melanoma incidence J:239472
Braftm1Mmcm/Braftm1Mmcm
Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+
Ptentm1Hwu/Pten+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6 		increased metastatic potential J:191327
increased prostate gland adenocarcinoma incidence J:191327
increased prostate gland tumor incidence J:191327
increased prostate intraepithelial neoplasia incidence J:191327
premature death J:191327
Braftm1Rima/Braf+
Tg(GFP/KRAS2/ALPP)1Brn/0
Tg(Tyr-cre/ERT2)1Lru/0
involves: C57BL/6 * DBA/2 * FVB/N 		increased melanoma incidence J:161180
Braftm1Rima/Braf+
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)1Lru/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 		hyperpigmentation J:161180
increased tumor incidence J:161180
Braftm1Sva/Braf+
Raf1tm2Bacc/Raf1tm2Bacc
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6 * SJL 		no abnormal phenotype detected J:121660
Braftm1Sva/Braftm1.1Sva
Raf1tm1Bacc/Raf1tm2Bacc
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL 		abnormal axon extension J:121660
abnormal dorsal root ganglion morphology J:121660
abnormal innervation J:121660
embryonic lethality during organogenesis, complete penetrance J:121660
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
involves: 129S1/Sv * 129X1/SvJ 		increased lung non-small cell carcinoma incidence J:172200
premature death J:172200
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ 		decreased cell proliferation J:172200
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Raf1tm2Bacc/Raf1tm2Bacc
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ 		decreased cell proliferation J:172200
Braftm1Sva/Braftm1Sva
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Raf1tm2Bacc/Raf1tm2Bacc
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ 		no abnormal phenotype detected J:172200
Braftm1Sva/Braftm1Sva
Raf1tm2Bacc/Raf1+
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL 		abnormal dorsal root ganglion morphology J:121660
abnormal innervation J:121660
abnormal sensory neuron innervation pattern J:121660
postnatal growth retardation J:121660
postnatal lethality, incomplete penetrance J:121660
Braftm1Sva/Braftm1Sva
Raf1tm2Bacc/Raf1tm2Bacc
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 		abnormal axon extension J:121660
Braftm1Tuv/Braftm1Tuv
Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+
Tg(Tyr-cre/ERT2)13Bos/0
TgTn(sb-T2/Onc)#Dla/0
involves: 129S6/SvEvTac * FVB/N 		increased melanoma incidence J:177503
Braftm1Wds/Braf+
Raf1tm2Bacc/Raf1tm2Bacc
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6 * SJL 		no abnormal phenotype detected J:121660
Braftm1Wds/Braftm1.1Wds
Raf1tm1Bacc/Raf1tm2Bacc
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL 		abnormal axon extension J:121660
abnormal dorsal root ganglion morphology J:121660
abnormal innervation J:121660
embryonic lethality during organogenesis, complete penetrance J:121660
Braftm1Wds/Braftm1Wds
Raf1tm2Bacc/Raf1+
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6 * SJL 		abnormal dorsal root ganglion morphology J:121660
abnormal innervation J:121660
abnormal sensory neuron innervation pattern J:121660
postnatal growth retardation J:121660
postnatal lethality, incomplete penetrance J:121660
Braftm1Wds/Braftm1Wds
Raf1tm2Bacc/Raf1tm2Bacc
involves: 129P2/OlaHsd * C57BL/6 		abnormal axon extension J:121660
Braftm1Wds/Braftm1Wds
Raf1tm2Bacc/Raf1tm2Bacc
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129P2/OlaHsd * C57BL/6J * CBA/J 		abnormal conotruncus morphology J:144862
abnormal thyroid gland morphology J:144862
double outlet right ventricle J:144862
normal growth/size/body region phenotype J:144862
normal hearing/vestibular/ear phenotype J:144862
lethality throughout fetal growth and development, complete penetrance J:144862
mandible hypoplasia J:144862
persistent truncus arteriosus J:144862
short maxilla J:144862
small thymus J:144862
small thyroid gland J:144862
ventricular septal defect J:144862
Braftm2Cpri/Braf+
Krastm4Tyj/Kras+
involves: 129S4/SvJae * C57BL/6 		increased fibroblast proliferation J:187371
increased lung adenoma incidence J:187371
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory